Search Results for "New Treatment For Hepatitis B"

09:27 EDT 16th September 2014 | BioPortfolio

Matching Channels

Hepatitis B

Hepatitis A

Hepatitis C

Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV R...

Autoimmune hepatitis

Hepatitis E virus HEV

Matching News

New Report: Innovation in Hepatitis C Treatment

Today, the California Healthcare Institute released a report on the public health impact of Hepatitis C and the potential of groundbreaking new treatments to save tens of thousands of lives over the c...

WHO Issues Its First Hepatitis C Treatment Guidelines

The World Health Organization (WHO) has issued its first guidance for the treatment of hepatitis C, a chronic infection that affects an estimated 130 million to 150 million people and results in 350,0...

Decade in review—HCV: Hepatitis C therapy—a fast and competitive race

The past 10 years have witnessed incredible developments in the treatment of hepatitis C. From an era in which the standard of care was PEG-IFN and ribavirin back in 2004, various interferon-free regi...

Breakthrough treatment for hepatitis C

(Medical Xpress)—A breakthrough treatment for hepatitis C that halves treatment time has been developed in an international clinical trial that included The University of Queensland.

Hepatitis B Virus Treatment Beyond the Guidelines

The aim of this review is to clarify how to treat hepatitis B and who should be treated, as well as when to stop treatment. Therapeutic Advances in Gastroenterology

A Home Run for Hepatitis C Treatment

Dr. William Balistreri describes the rapidly evolving landscape of hepatitis C treatment. Medscape Gastroenterology

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works...

$1,000-a-Day Hepatitis C Drug Is a Blockbuster

Runaway demand for a life-saving hepatitis C treatment that costs $1,000 a day could send insurers' earnings per share down by double-digit percentages this year. Read more about $1,000-a-Day Hepatiti...

Matching PubMed Articles

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study.

The off-treatment durability of nucleos(t)ide analogue therapy in Asian hepatitis B e antigen (HBeAg) negative chronic hepatitis B (CHB) and the role of hepatitis B surface antigen (HBsAg) levels in p...

Distribution of hepatitis C virus genotypes among patients with hepatitis C virus infection in hormozgan, iran.

More than 170 million people in the world are infected with Hepatitis C virus (HCV). Determination of HCV genotype before starting the treatment is required, because HCV genotype affects the course of...

Classical and Modern Approaches Used for Viral Hepatitis Diagnosis.

Viral hepatitis diagnosis is an important issue in the treatment procedure of this infection. Late diagnosis and delayed treatment of viral hepatitis infections can lead to irreversible liver damages ...

Sofosbuvir: First Global Approval.

Sofosbuvir (Solvadi™), a nucleotide analogue hepatitis C virus NS5B polymerase inhibitor, is under development with Gilead Sciences for the once-daily, oral treatment of chronic hepatitis C. Oral so...

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.

Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was to determine the assoc...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement